说明:II型神经纤维瘤病(Neurofibromatosis type II,NF2)是一种罕见的遗传性疾病,常见的症状是听觉丧失和去平衡,这两者都强烈地影响患者的生活质量。目前可找到的功能研究并不多。在Torres-Martin等人进行的研究中(Torres-Martin等,2012)提供了神经鞘瘤的基因表达谱数据,而且上传到了GEO数据库中,被GENEVESTIGATOR软件所收录。
在这项研究中,使用GENEVESTIGATOR,比较这种疾病中与其他癌症类型,并鉴定在该疾病中特异性调节的基因。虽然在分析时,只有极少的关于NF2的转录组研究发表,但通过分析可以发现,在转录水平上,NF2最类似于ERBB2阳性乳腺癌。确定了几个候选靶标,开辟治疗干预的新途径。
5. 此外,如果对于这两种蛋白质已经存在特异性抑制剂,它们可能是 NF2 治疗的有价
值的候选。
讨论:
虽然 II 型神经纤维瘤病(Neurofibromatosis type II,NF2)的转录组数据不多,但是
通过分析,寻找到了与 NF2 癌症具有相似基因表达分子标签的病理状况,揭示了与
乳腺癌,特别是与 ERBB2 阳性癌症的密切关系。这一发现得到了最近的临床试验重
新定位乳腺癌药物对 NF2 治疗的证实(发现一)。
寻找在 NF2 中特异性表达的基因。 确定了一种非常有趣的细胞表面蛋白编码基因
GFRA3,为药物开发和疾病治疗开辟了新的可能(发现二)。
延申阅读:
Beguelin, W., Diaz Flaque, M.C., Proietti, C.J., Cayrol, F., Rivas, M.A., Tkach, M., Rosemblit, C., Tocci, J.M., Charreau, E.H., Schillaci, R., et al.
(2010) Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect:
ErbB-2 function as a coactivator of Stat3 Molecular and cellular biology 30, 5456-5472.
Curto, M., Cole, B.K., Lallemand, D., Liu, C.H., and McClatchey, A.I. (2007) Contact-dependent inhibition of EGFR signaling by
Nf2/Merlin. The Journal of cell biology 177, 893-903.
den Bakker, M.A., Vissers, K.J., Molijn, A.C., Kros, J.M., Zwarthoff, E.C., and van der Kwast, T.H. (1999) Expression of the neurofibromatosis
type 2 gene in human tissues. J Histochem Cytochem 47, 1471-1480.
Evans, D.G. (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet journal of rare diseases 4, 16.
6. Evans, D.G., Sainio, M., and Baser, M.E. (2000) Neurofibromatosis type 2. Journal of medical genetics 37, 897-904.
Hansen, M.R., Roehm, P.C., Chatterjee, P., and Green, S.H. (2006) Constitutive neuregulin-1/ErbB signaling contributes to human
vestibular schwannoma proliferation. Glia 53, 593-600.
Hartman, Z.C., Yang, X.Y., Glass, O., Lei, G., Osada, T., Dave, S.S., Morse, M.A., Clay, T.M., and Lyerly, H.K. (2011) Title HER2 overexpression
elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.
Lallemand, D., Manent, J., Couvelard, A., Watilliaux, A., Siena, M., Chareyre, F., Lampin, A., Niwa-Kawakita, M., Kalamarides, M., and Giovannini,
M. (2009) Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann
cells and in human schwannomas. Oncogene 28, 854-865.
Li, W., Cooper, J., Karajannis, M.A., and Giancotti, F.G. (2012) Merlin: a tumour suppressor with functions at the cell cortex and in the
nucleus. EMBO reports 13, 204-215.
Mautner, V.F., Nguyen, R., Kutta, H., Fuensterer, C., Bokemeyer, C., Hagel, C., Friedrich, R.E., and Panse, J. (2010) Bevacizumab induces
regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-oncology 12, 14-18.
McClatchey, A.I., and Giovannini, M. (2005) Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes &
development 19, 2265-2277.
Morrow, K.A., Das, S., Metge, B.J., Ye, K., Mulekar, M.S., Tucker, J.A., Samant, R.S., and Shevde, L.A. (2011) Loss of tumor suppressor
Merlin in advanced breast cancer is due to post-translational regulation. The Journal of biological chemistry 286, 40376-40385.
Regis, J., Carron, R., Moucharrafien, S., Delsantin, C., Porcheron, D., Thomassin, J.M., Murracciole, X., and Roche, P.H. (2012) Role of
radiosurgery and stereotactic radiotherapy in the management of vestibular schwannomas Cancer Radiother 16 Suppl, S70-78.
7. Stonecypher, M.S., Chaudhury, A.R., Byer, S.J., and Carroll, S.L. (2006) Neuregulin growth factors and their ErbB receptors form a potential
signaling network for schwannoma tumorigenesis. Journal of neuropathology and experimental neurology 65, 162-175.